1319 related articles for article (PubMed ID: 25194181)
21. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches.
Soto-Angona Ó; Anmella G; Valdés-Florido MJ; De Uribe-Viloria N; Carvalho AF; Penninx BWJH; Berk M
BMC Med; 2020 Oct; 18(1):261. PubMed ID: 32998725
[TBL] [Abstract][Full Text] [Related]
22. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.
Barchetta I; Cimini FA; Cavallo MG
Nutrients; 2020 Oct; 12(11):. PubMed ID: 33126575
[TBL] [Abstract][Full Text] [Related]
23. Nonalcoholic Fatty Liver Disease in South Asia.
Pati GK; Singh SP
Euroasian J Hepatogastroenterol; 2016; 6(2):154-162. PubMed ID: 29201749
[TBL] [Abstract][Full Text] [Related]
24. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter.
Chiriac S; Stanciu C; Girleanu I; Cojocariu C; Sfarti C; Singeap AM; Cuciureanu T; Huiban L; Muzica CM; Zenovia S; Nastasa R; Trifan A
Can J Gastroenterol Hepatol; 2021; 2021():6696857. PubMed ID: 33505944
[TBL] [Abstract][Full Text] [Related]
25. Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key.
Alonso-Peña M; Del Barrio M; Peleteiro-Vigil A; Jimenez-Gonzalez C; Santos-Laso A; Arias-Loste MT; Iruzubieta P; Crespo J
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445895
[TBL] [Abstract][Full Text] [Related]
26. Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD).
Conlon BA; Beasley JM; Aebersold K; Jhangiani SS; Wylie-Rosett J
Nutrients; 2013 Oct; 5(10):4093-114. PubMed ID: 24152749
[TBL] [Abstract][Full Text] [Related]
27. Metabolic Associated Fatty Liver Disease in Children and Adolescents: Mechanisms of a Silent Epidemic and Therapeutic Options.
Mosca A; Volpe LD; Sartorelli MR; Comparcola D; Veraldi S; Alisi A; Maggiore G
Curr Pediatr Rev; 2024; 20(3):296-304. PubMed ID: 37013431
[TBL] [Abstract][Full Text] [Related]
28. NAFLD as the metabolic hallmark of obesity.
Rojano A; Sena E; Manzano-Nuñez R; Pericàs JM; Ciudin A
Intern Emerg Med; 2023 Jan; 18(1):31-41. PubMed ID: 36357606
[TBL] [Abstract][Full Text] [Related]
29. NAFLD and cardiovascular diseases: a clinical review.
Kasper P; Martin A; Lang S; Kütting F; Goeser T; Demir M; Steffen HM
Clin Res Cardiol; 2021 Jul; 110(7):921-937. PubMed ID: 32696080
[TBL] [Abstract][Full Text] [Related]
30. Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network?
Heitmann J; Frings VG; Geier A; Goebeler M; Kerstan A
J Dtsch Dermatol Ges; 2021 Apr; 19(4):517-528. PubMed ID: 33768700
[TBL] [Abstract][Full Text] [Related]
31. Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights.
Ikejima K; Kon K; Yamashina S
Clin Mol Hepatol; 2020 Oct; 26(4):728-735. PubMed ID: 33053942
[TBL] [Abstract][Full Text] [Related]
32. Anthocyanins: Potential phytochemical candidates for the amelioration of non-alcoholic fatty liver disease.
Mandal B; Das R; Mondal S
Ann Pharm Fr; 2024 May; 82(3):373-391. PubMed ID: 38354975
[TBL] [Abstract][Full Text] [Related]
33. [Descriptive study of hepatic steatosis and associated morbidity in Primary Care. (ESTEATOAP Study)].
Cortés Rubio JA; Costa Zamora P; Guerra Díaz R; Candela Fernández M; Cortés Costa M
Semergen; 2020 Sep; 46(6):400-405. PubMed ID: 32249131
[TBL] [Abstract][Full Text] [Related]
34. Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application.
Xu Y; Guo W; Zhang C; Chen F; Tan HY; Li S; Wang N; Feng Y
Front Pharmacol; 2020; 11():601. PubMed ID: 32477116
[TBL] [Abstract][Full Text] [Related]
35. Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges.
Dooghaie Moghadam A; Eslami P; Razavi-Khorasani N; Moazzami B; Zahedi-Tajrishi F; Farokhi E; Makhdoomi Sharabiani K; Mansour-Ghanaei A; Mehrvar A; Aghajanpoor Pasha M; Saeedi S; Iravani S
Caspian J Intern Med; 2020; 11(4):346-354. PubMed ID: 33680375
[TBL] [Abstract][Full Text] [Related]
36. Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications.
Furuta K; Tang X; Islam S; Tapia A; Chen ZB; Ibrahim SH
Pharmacol Ther; 2023 Apr; 244():108372. PubMed ID: 36894027
[TBL] [Abstract][Full Text] [Related]
37. Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review.
Kobayashi T; Iwaki M; Nogami A; Honda Y; Ogawa Y; Imajo K; Saito S; Nakajima A; Yoneda M
Nutrients; 2023 Mar; 15(5):. PubMed ID: 36904268
[TBL] [Abstract][Full Text] [Related]
38. Innate immunity and nonalcoholic fatty liver disease.
Kountouras J; Kazakos E; Kyrailidi F; Polyzos SA; Zavos C; Arapoglou S; Boziki M; Mouratidou MC; Tzitiridou-Chatzopoulou M; Chatzopoulos D; Doulberis M; Papaefthymiou A; Vardaka E
Ann Gastroenterol; 2023; 36(3):244-256. PubMed ID: 37144011
[TBL] [Abstract][Full Text] [Related]
39. Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome.
Esmail VAW; Mohammed MO; Al-Nimer MSM
Arab J Gastroenterol; 2021 Mar; 22(1):1-5. PubMed ID: 33664007
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
